"TO THRIVE AS A FIELD, DIGITAL MEDICINE REQUIRES AN UNPRECEDENTED LEVEL OF INTERDISCIPLINARY COLLABORATION. FROM REGULATORS TO WHITE-HAT HACKERS, ETHICISTS TO ENGINEERS, AND CLINICIANS TO CITIZEN SCIENTISTS, NEW COOPERATIVE NETWORKS MUST EMERGE TO ENSURE THAT DIGITAL MEDICINE REALIZES ITS FULL POTENTIAL TO IMPROVE HUMAN HEALTH." (DIGITAL MEDICINE SOCIETY)
Returning to Pfizer in Cambridge, the Digital Implementation Forum focuses on ways for life sciences to take advantage of new opportunities within digital health and digital measurement; as well as how these new data can supplement existing collection strategies to drive research forward. Be a part of the movement to get these validated digital measures and digital health tools (DHTs) into the hands of patients, their physicians and caregivers.
Join 30+ speakers, 180+ senior-level pharma, clinical trials, technology and digital health executives this November 3, 2026 at Pfizer in Cambridge to learn, network, develop and improve the way digital health measurement tools are being created, validated, scaled and deployed in life sciences to improve data quality, improve patient experience & accelerate drug development and patient care.
For 2026, the event will be once again co-created and led by both Pfizer & Johnson & Johnson Innovative Medicine. This collaborative approach is exciting for the field and shows the true nature of this event from its inception; a place for all at the table!
Join 30+ speakers, 180+ senior-level pharma, clinical trials, technology and digital health executives this November 3, 2026 at Pfizer in Cambridge to learn, network, develop and improve the way digital health measurement tools are being created, validated, scaled and deployed in life sciences to improve data quality, improve patient experience & accelerate drug development and patient care.
For 2026, the event will be once again co-created and led by both Pfizer & Johnson & Johnson Innovative Medicine. This collaborative approach is exciting for the field and shows the true nature of this event from its inception; a place for all at the table!
Location
Date & Time
November 3, 2026
9:00am - 5:30pm
9:00am - 5:30pm
2026 CORE THEMES
1. Pathways to Value Creation from Investment in Digital Measures
• How investment in digital measures is creating value beyond capturing disease progression in ways that matter to patients and clinicians
• How to build confidence with investigators, sites, HCPs and patients and show clear value in care
• Discussions around ROI and context of use
• How to build confidence with investigators, sites, HCPs and patients and show clear value in care
• Discussions around ROI and context of use
2. Burgeoning Applications of Digital Measures in Clinical Development: Opportunities around Stratification, Classification & Label Expansion
• Digital phenotyping to standardize patient categorization, reduce cohort heterogeneity, and optimize trial population selection
• Tracking subtle disease trajectories and detecting early-stage shifts to capture changes in progression missed by episodic clinical scales
• Opportunities to deliver more value to patients and achieve label expansion
3. Looking Towards the Future of Integrated Multimodal Biomarkers in Clinical Trials
• How combining continuous digital data (e.g., actigraphy, sleep patterns, vocal biomarkers) with traditional analog measures (e.g., lab tests, advanced imaging, EHR, and genomics) can accelerate clinical research
• What it takes to use machine learning models to synthesize multiple streaming features into a single composite endpoint
4. Considerations From Discovery to Development: Managing Expectations, Key Learnings and getting to the Finish Line
• The latest regulatory approval pathways & advances for digital measures: the state of the space
• Stakeholder collaborations leading progress for AI co-science - opportunities and hurdles in both query and foundation models
• Regulatory experts discuss hot topics: AI-driven decision support, digital endpoint validation, decentralized oversight, and the evolving role of real-world data.
2026 Speakers and Advisors
Carrie Northcott
Head of Digital Medicine and Translational Imaging
(Pfizer Chair)
Head of Digital Medicine and Translational Imaging
(Pfizer Chair)
Charmaine Demanuele
VP, Data Science & Digital Health
(J&J Chair)
VP, Data Science & Digital Health
(J&J Chair)
Phil Murphy
Head of Imaging & Digital Health
(J&J Chair)
Head of Imaging & Digital Health
(J&J Chair)
Srinivasan Vairavan
Director, Digital and AI Biomarkers
Director, Digital and AI Biomarkers
Jay Fang
Director, HVE, Patient-Centered Outcome Assessment
Director, HVE, Patient-Centered Outcome Assessment
Bola Grace
Professor of Practice
Professor of Practice
Kevin Maresca
Head of Clinical & Translational Imaging
Head of Clinical & Translational Imaging
Matt Czech
Associate Director, Data Science
Associate Director, Data Science
Pirinka Tuttle
Director, Project Lead, Digital Medicine & Translational Imaging
Director, Project Lead, Digital Medicine & Translational Imaging
Kevin "Kip" Thomas
Director
Director
Thomas Bartlett
Rare Disease Patient & Advocate
Rare Disease Patient & Advocate
Anahita Kyani
Director, Neuroscience Data & Digital Health
Director, Neuroscience Data & Digital Health
Daniel Karlin
Chief Medical Officer
Chief Medical Officer
Isaac Galatzer-Levy
Senior Staff Research Scientist
Senior Staff Research Scientist
Rebecca Shilling
Clinical Development Asset Lead
Clinical Development Asset Lead
Kate Lyden
Director of Science
Director of Science
Laura Taraboanta
Project Lead, Digital Medicine & Translational Imaging
Project Lead, Digital Medicine & Translational Imaging
Jared Worful
Head of Digital Health Technology & Real-World Science
Head of Digital Health Technology & Real-World Science
Jacqueline Thong
General Manager, US
General Manager, US
Ryan Barraco
Director, Regulatory Policy
Director, Regulatory Policy
Bhaskar Dutta
Head, Digital Health and Medical Affairs Technologies
Head, Digital Health and Medical Affairs Technologies
Derek Hill
Professor, Digital Health
Professor, Digital Health
Kara Chappie
Project Lead, Digital Medicine & Translational Imaging
Project Lead, Digital Medicine & Translational Imaging
Agenda: November 3, 2026
8:00 AM
Registration, Coffee and Conversation
Conference registration open with continental breakfast and coffee served
9:00 AM
Opening Remarks from Conference Chairs
Carrie Northcott, Head of Digital Medicine and Translational Imaging, Pfizer (Pfizer Chair)
Charmaine Demanuele, VP, Data Science & Digital Health, Johnson & Johnson Innovative Medicine (J&J Chair)
Phil Murphy, Head of Imaging & Digital Health, Johnson & Johnson Innovative Medicine (J&J Chair)
9:10 AM
Pathways to Value Creation from Investment in Digital Measures
Session Chair
Carrie Northcott, Head of Digital Medicine and Translational Imaging, Pfizer (Pfizer Chair)
9:15 AM
Validation of the DHT-derived non-sedentary activity time measure for cancer cachexia
Jay Fang, Director, HVE, Patient-Centered Outcome Assessment, Pfizer
9:30 AM
ROI Of Digital Measures: Value Delivered
Kate Lyden, Chief Science Officer, Vivosense
Rebecca Shilling, Clinical Development Asset Lead, argenx
9:45 AM
PANEL DISCUSSION:
Pathways to Value Creation from Investment in Digital Measures
- How investment in digital measures is creating value beyond capturing disease progression in ways that matter to patients and clinicians
- How to build confidence with investigators, sites, HCPs and patients and show clear value in care
- Discussions around ROI and context of use
Kevin “Kip” Thomas, Director, Boston University
Jay Fang, Director, HVE, Patient-Centered Outcome Assessment, Pfizer
Thomas Bartlett, Rare Disease Patient & Advisor - Myasthenia Gravis
Speaker TBA, AliveCor
10:15 AM
NETWORKING COFFEE BREAK
10:50 AM
Burgeoning Applications of Digital Measures in Clinical Development: Opportunities around Stratification, Classification & Label Expansion
Kara Chappie, Project Lead, DMTI, Pfizer (Session Chair)
10:50 aM
Disease-stage Specific Digital Health Technology Biomarkers can Enhance Sensitivity to Severity
Matt Czech, Associate Director, Digital Science, AbbVie
11:05 aM
Presentation TBA
11:20 aM
RWE and Digital Measurement of Abrocitinib Effects on Scratch and Sleep
Pirinka Tuttle, Director, Digital Medicine & Translational Imaging, Pfizer
11:35 AM
PANEL DISCUSSION:
Burgeoning Applications of Digital Measures in Clinical Development: Opportunities around Stratification, Classification & Label Expansion
- Digital phenotyping to standardize patient categorization, reduce cohort heterogeneity, and optimize trial population selection
- Tracking subtle disease trajectories and detecting early-stage shifts to capture changes in progression missed by episodic clinical scales
- Opportunities to deliver more value to patients and achieve label expansion
Daniel Karlin, Chief Medical Officer, Definium Therapeutics
Bhaskar Dutta, Head, Digital Health and Medical Affairs Technologies, Alexion Pharmaceuticals
Phil Murphy, Head of Imaging and Digital Health, Johnson & Johnson
12:05 PM
NETWORKING LUNCHEON
1:05 PM
Looking Towards Multimodal Digital Biomarkers in Clinical Trials
Phil Murphy, Head of Imaging and Digital Health, Johnson & Johnson (Session Chair)
1:10 PM
Presentation TBA
1:25 PM
Insights from Speech, PET and P-tau217 in Early Alzheimer's Disease
Anahita Koyani, Director, Neuroscience Digital Biomarkers, Johnson & Johnson Innovative Medicine
1:40 PM
Presentation TBA
2:05 PM
PANEL DISCUSSION:
Integrated Multimodal Digital Biomarkers in Clinical Trials
- How combining continuous digital data (e.g., actigraphy, sleep patterns, vocal biomarkers) with traditional analog measures (e.g., lab tests, advanced imaging, EHR, and genomics) can accelerate clinical research
- What it will take to use machine learning models to synthesize multiple streaming features into a single composite endpoint
Isaac Galatzer-Levy, Senior Staff Research Scientist, Google DeepMind
Derek Hill, Professor of Digital Health, UCL
Srinivasan Vairavan, Director, Data Science, Digital Health, Johnson & Johnson Innovative Medicine
Kevin Maresca, Head of Clinical & Translational Imaging, Pfizer
2:30 PM
NETWORKING COFFEE AND REFRESHMENT BREAK
3:00 PM
Considerations From Discovery to Development: Managing Expectations, Key Learnings and getting to the Finish Line
Carrie Northcott, Head of Digital Medicine and Translational Imaging, Pfizer (Session Chair)
3:00 PM
Presentation TBA
3:15 PM
PANEL DISCUSSION:
The Foundational Content Consolidation initiative - a structured ''reduce, reuse, and recycle” approach for turning fragmented content into regulatory-ready evidence
Jared Worful, Head of Digital Health Technology & Real-World Science, Bayer
Carrie Northcott, Head of Digital Medicine and Translational Imaging, Pfizer
Jacqueline Thong, General Manager, US, DEEP Measures
3:40 PM
PANEL DISCUSSION:
Managing Regulatory Expectations - Collaborations, Key Learnings and getting to the Finish Line
Laura Taraboanta, Project Lead, Digital & Translational Imaging, Pfizer
Bola Grace, Professor of Practice, UCL
Kate Lyden, Chief Science Officer, Vivosense
Ryan Barraco, Director, Regulatory Policy, Johnson & Johnson Innovative Medicine
4:00 - 5:30 PM
NETWORKING RECEPTION
HOST SPONSOR
CO-HOST
GOLD SPONSOR
SILVER SPONSOR
SILVER SPONSOR
EXHIBITOR
SUPPORTING SPONSOR
SUPPORTING SPONSOR
SUPPORTING SPONSOR
Interested in Sponsorship & Exhibition Opportunities?
Location
Pfizer Innovation Research (PfIRe) Lab
Cambridge, MA
Cambridge, MA
The PfIRe Lab is a highly instrumented clinical research facility located in Cambridge, Massachusetts. Here, researchers use cutting-edge wearable and environmental sensors to develop and validate novel, patient-centric clinical endpoints, thereby potentially enabling a better understanding of a patient’s disease state and response to therapy.
Pfizer’s Digital Medicine & Translational Imaging Team recently unveiled this industry-leading facility in Cambridge, Massachusetts, designed to rapidly evaluate and validate novel technologies for potential use in clinical trials. In the PfIRe Lab, a multidisciplinary team of clinicians and researchers utilize state-of-the-art motion capture technologies, coupled with environmental and wearable sensors to develop new patient-centric clinical trial endpoints, enabling measures of physical function and activity outside of the traditional hospital and clinical settings.
Pfizer’s Digital Medicine & Translational Imaging Team recently unveiled this industry-leading facility in Cambridge, Massachusetts, designed to rapidly evaluate and validate novel technologies for potential use in clinical trials. In the PfIRe Lab, a multidisciplinary team of clinicians and researchers utilize state-of-the-art motion capture technologies, coupled with environmental and wearable sensors to develop new patient-centric clinical trial endpoints, enabling measures of physical function and activity outside of the traditional hospital and clinical settings.
Join us at the
Digital Implementation Summit 2026!
Digital Implementation Summit 2026!
The Premiere Event focused on Digital Measurements Developed for Clinical Research to ultimate Clinical Utility; for the Benefit of Patients and their Healthcare Providers